Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bin Seo, Yu | - |
dc.contributor.author | Choi, Won Suk | - |
dc.contributor.author | Lee, Jacob | - |
dc.contributor.author | Song, Joon Young | - |
dc.contributor.author | Cheong, Hee Jin | - |
dc.contributor.author | Kim, Woo Joo | - |
dc.date.accessioned | 2021-09-03T10:46:10Z | - |
dc.date.available | 2021-09-03T10:46:10Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-01-25 | - |
dc.identifier.issn | 2287-3651 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/84874 | - |
dc.description.abstract | Purpose: Previous studies have demonstrated the immunogenicity and safety of the co-administration of the trivalent inactivated influenza vaccine IIV3) with the polysaccharide pneumococcal vaccine PPV) or pneumococcal conjugate vaccine PCV). However, there is no direct comparison study that evaluates the immunogenicity and safety of IIV3 given concomitantly with PCV13 or PPV23 in the elderly. Materials and Methods: During the 2012-2013 influenza vaccination period, 224 healthy elderly volunteers aged 65 years and older randomly received IIV3 given concomitantly with either PCV13 PCV13IIV3) or PPV23 PPV23IIV3) in a 1: 1 ratio. Serum hemagglutination-inhibiting antibodies for IIV3 were measured at the time of vaccination and 1 month after vaccination. Adverse events were recorded prospectively in a clinical diary during a 7-day period. Results: A total of 220 participants blood samples for analysis of immunogenicity and kept a clinical diary for safety analysis PCV13IIV3, n= 110; PPV23IIV3, n= 110). One month after vaccination, both groups satisfied the Committee for Medical Products for Human Use criteria for A/H1N1, A/H3N2 and B strains, showing comparable seroprotection rates, seroconversion rates and geometric mean titer fold. The assessments of immunogenicity were similar in both groups. The most common local and systemic reactions were pain at the injection site and generalized myalgia. They were generally mild or moderate in intensity. The adverse events were not statistically different between the two groups. Conclusion: PCV13IIV3 and PPV23IIV3 demonstrated similar immunogenicity and safety in the elderly. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN VACCINE SOC | - |
dc.subject | CHRONIC LUNG-DISEASE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | ADULTS | - |
dc.subject | TRIAL | - |
dc.subject | OLDER | - |
dc.subject | PEOPLE | - |
dc.title | Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Won Suk | - |
dc.identifier.doi | 10.7774/cevr.2017.6.1.38 | - |
dc.identifier.scopusid | 2-s2.0-85029176464 | - |
dc.identifier.wosid | 000396614500006 | - |
dc.identifier.bibliographicCitation | CLINICAL AND EXPERIMENTAL VACCINE RESEARCH, v.6, no.1, pp.38 - 44 | - |
dc.relation.isPartOf | CLINICAL AND EXPERIMENTAL VACCINE RESEARCH | - |
dc.citation.title | CLINICAL AND EXPERIMENTAL VACCINE RESEARCH | - |
dc.citation.volume | 6 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 38 | - |
dc.citation.endPage | 44 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002326694 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | CHRONIC LUNG-DISEASE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | ADULTS | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | OLDER | - |
dc.subject.keywordPlus | PEOPLE | - |
dc.subject.keywordAuthor | Pneumococcus | - |
dc.subject.keywordAuthor | Influenza | - |
dc.subject.keywordAuthor | Vaccine | - |
dc.subject.keywordAuthor | Immunogenicity | - |
dc.subject.keywordAuthor | Safety | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.